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Ampliﬁcation Tests for Inﬂuenza A/B Virus Detection in
Children
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ABSTRACT Early diagnosis of inﬂuenza (Flu) is critical for patient management and
infection control. The ID Now inﬂuenza A & B 2 (ID Now) assay (Abbott Laboratories), Cobas inﬂuenza A/B nucleic acid test (LIAT; Roche Molecular Systems, Inc.), and
Xpert Xpress Flu (Xpert; Cepheid) are rapid, point-of-care molecular assays for Flu virus detection. The study aim was to compare the performances of these three commercially available Clinical Laboratory Improvement Amendments (CLIA)-waived Flu
virus assays. We prospectively enrolled 201 children ⬍18 years old from January to
April 2018 and collected nasopharyngeal swab specimens in viral medium. Aliquots
were frozen for testing on different diagnostic platforms, as per the manufacturers’
instructions. CDC Flu A/B PCR was used as a reference method to evaluate the performances of these three platforms. Among the 201 specimens tested, the CDC Flu
A/B PCR assay detected Flu A/B virus in 107 samples (Flu A virus, 73 samples; Flu B
virus, 36 samples; dual Flu A/B virus positive, 2 samples), while the ID Now virus detected 102 samples (Flu A virus, 69 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4 samples; invalid rate, 1/201 [0.5%]), the LIAT detected 112 samples
(Flu A virus, 74 samples; Flu B virus, 38 samples; invalid rate, 11/201 [5.5%]), and the
Xpert assay detected 112 samples (Flu A virus, 76 samples; Flu B virus, 36 samples;
invalid rate, 6/201 [3.0%]). The overall sensitivities for the ID Now assay, LIAT, and
Xpert assay for Flu A virus detection (93.2%, 100%, and 100%, respectively) and Flu
B virus detection (97.2%, 94.4%, and 91.7%, respectively) were comparable. The
speciﬁcity for Flu A and B virus detection by all methods was ⬎97%. These molecular assays had higher sensitivity than did a historical standard-of-care test from the
BD Veritor antigen test (Flu A virus, 79.5%; Flu B virus, 66.7%).
KEYWORDS children, inﬂuenza detection, molecular diagnostic assays performance

R

espiratory infection by inﬂuenza (Flu) virus is capable of causing severe illness
resulting in hospitalization and death in young children and the elderly (1, 2). Early
diagnosis of inﬂuenza virus is critical for patient management, infection control, and
reduction of health care costs (3–5). Various inﬂuenza virus testing methods are
available, including antigen detection-based assays (rapid inﬂuenza diagnostic assays
[RIDTs] and immunoﬂuorescence assays), molecular assays (rapid molecular assays,
reverse transcription-PCR [RT-PCR], and other nucleic acid ampliﬁcation assays), and
viral culture (https://www.cdc.gov/ﬂu/professionals/diagnosis/overview-testing-methods
.htm). Sensitivities and speciﬁcities vary among the various methods currently approved
for detecting Flu A and B viruses (4, 6). The list of Food and Drug Administration
(FDA)-cleared molecular assays for inﬂuenza virus detection can be found at https://
www.cdc.gov/ﬂu/pdf/professionals/diagnosis/table1-molecular-assays.pdf. Molecular assays provide higher sensitivity and speciﬁcity than do RIDTs. Rapid, point-of-care
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molecular assays yield results that are available in approximately 30 min (7). The
Infectious Diseases Society of America (IDSA) recommends using rapid inﬂuenza molecular assays over RIDTs for detecting inﬂuenza virus in specimens from suspected
respiratory infection patients in the outpatient clinical setting (8).
The ID Now inﬂuenza A & B 2 (ID Now) assay (Abbott, IL; formerly known as Alere
i inﬂuenza A/B 2), Cobas inﬂuenza A/B nucleic acid test (LIAT; Roche Molecular Systems,
Inc., Indianapolis, IN), and Xpert Xpress Flu (Xpert) assay (Cepheid, Sunnydale, CA) are
FDA-cleared, rapid, point-of-care detection systems for inﬂuenza virus. ID Now uses
isothermal nucleic acid ampliﬁcation technology based on nicking enzyme ampliﬁcation reaction (NEAR) technology, while the LIAT and the Xpert assay are real-time
RT-PCR assays. All three platforms use single-use test units containing target-speciﬁc
reagents where the extraction, ampliﬁcation, and detection of inﬂuenza A and B viral
RNA take place. This research study was designed to compare the performance of these
three Clinical Laboratory Improvement Amendments (CLIA)-waived Flu virus molecular
detection systems (ID Now assay, LIAT, and Xpert assay) using nasopharyngeal swab
specimens collected from children during the 2017–2018 respiratory season. The
performance of each system was evaluated against the CDC Flu A/B PCR. The results
from the BD Veritor Flu A/B antigen test (BD Diagnostics, Sparks, MD) were obtained
from standard-of-care testing and compared with those from the three molecular
assays.
MATERIALS AND METHODS
Study design and specimens. This prospective clinical trial was conducted from January to April
2018 at Children’s Mercy Hospitals and Clinics in Kansas City, MO, USA, to evaluate the performances of
three molecular assays (ID Now, LIAT, and Xpert) and an antigen-based BD assay. The study samples
came from 201 male and female subjects between the ages of 0 and 200 months (median, 42 months)
with suspected respiratory infections. Subjects with a physician’s order for a Flu test were eligible to
participate in the study. After the standard-of-care test was completed, the subject was approached and
enrolled in the study. Following parental permission and the child’s assent when appropriate, a
nasopharyngeal swab specimen was obtained and saved in 3 ml of universal transport medium. Each
specimen was given a unique study identiﬁer at the time of study enrollment. Five aliquots of 300 l
were made and frozen at –70°C. Aliquots 1, 2, and 3 were thawed once before testing by the ID Now
assay, LIAT, and Xpert assay at a later date. Aliquot 4 was thawed and extracted on the NucliSENS
easyMAG instrument (bioMérieux, Inc., Durham, NC, USA). Nucleic acid aliquots were prepared for
performing the CDC Flu A/B PCR in a batch mode. Aliquot 5 was kept as a backup aliquot for any repeat
runs resulting from invalid results and also for running a subset of the samples on the early callout mode
on the ID Now platform. BD Veritor antigen test results were obtained from standard-of-care testing;
results for 200 subjects were available, with one of the subjects having a PCR-based assay ordered for
standard-of-care testing. The results for all three molecular assays and the results from the BD antigen
assay were compared with results from the reference FDA-cleared inﬂuenza PCR assay (CDC Flu A/B PCR).
Positive and negative controls were run on a weekly basis on all three molecular assays. Invalid results
were retested once.
CDC Flu A/B PCR test. Nucleic acid extraction was performed with the NucliSENS easyMAG system
from a 200-l sample (aliquot 4) containing 20 l of universal internal control along with positive and
negative extraction controls, according to the manufacturer’s instructions; the nucleic acid obtained was
eluted in 110 l of elution buffer. The sample eluate was aliquoted into two separate Eppendorf tubes
and stored at ⫺80°C until further testing. CDC Flu A/B PCR is a real-time RT-PCR-based assay that was
performed on an Applied Biosystems 7500 Fast Dx system (Thermo Fisher Scientiﬁc Corp., MA, USA) with
software version 1.4. The assay targets a region of the matrix gene of inﬂuenza A virus and a region of
the nonstructural protein gene of inﬂuenza B virus. Oligonucleotide primers and probes for characterization and differentiation of inﬂuenza A subtypes (pandemic H1N1 [pH1N1] and H3N2 virus strains) and
genetic lineages of inﬂuenza B virus (Yamagata and Victoria) target highly conserved regions of the
hemagglutinin (HA) gene. The results from this assay were used for the sensitivity and speciﬁcity
analyses.
ID Now assay. The ID Now assay is an isothermal nucleic acid ampliﬁcation-based, sample-to-answer
assay indicated for use on the ID Now platform for the detection and differentiation of inﬂuenza A virus
and inﬂuenza B virus. The test targets polymerase basic gene 2 (PB2) for inﬂuenza A virus and polymerase
acidic gene (PA) for inﬂuenza B virus detection. The test uses 200 l of sample volume. Results are
provided in approximately 15 min, including upfront 3 minutes of sample elution buffer warm-up time,
followed by the assay run time. The early callout mode is an early detection feature of the new ID Now
assay that allows the assay to end as soon as a positive result is detected in one of the targets (Flu A or
Flu B virus). The assay run time on the ID Now platform was within 2 to 5 min for a positive call in the
early callout mode as opposed to less than 13 min on the full-callout mode. The time taken for a negative
result call on the early callout mode was similar to that with the full-callout mode. The warm-up time
required for the sample elution buffer in the newer version is reduced by half, from 6 min to 3 min. The
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manufacturer’s instructions were followed to perform the assay; the detailed method can be found in an
earlier publication (9). The performance characteristics presented in the manuscript were results from
samples run on the full-callout mode. A subset of 102 samples was run on the early callout mode with
aliquot 5 to determine the approximate time to result and agreement between the results from the two
callout modes.
Cobas inﬂuenza A/B nucleic acid test. The Cobas inﬂuenza A/B nucleic acid test is a sample-toanswer system and real-time RT-PCR-based assay indicated for use on the Cobas LIAT PCR system (Roche
Diagnostics, Indianapolis, IN). The assay targets a region of the matrix gene of inﬂuenza A virus and a
region of the nonstructural protein gene of inﬂuenza B virus. The test uses 200 l of sample volume, and
results are provided in 20 min, with a hands-on time of less than 5 min. The manufacturer’s instructions
were followed to perform the assay.
Xpert Xpress Flu assay. The Xpert Xpress Flu sample-to-answer assay is a real-time RT-PCR-based
assay for the detection and differentiation of inﬂuenza A and B viral RNA. The samples were tested by
the CLIA-waived assay on the Cepheid GeneXpert Xpress II system. The assay targets unique gene
sequences that encode inﬂuenza A matrix (M), inﬂuenza A basic polymerase (PB2), and inﬂuenza A acidic
(PA) proteins for inﬂuenza A virus and inﬂuenza B matrix (M) and inﬂuenza B nonstructural (NS) proteins
for inﬂuenza B virus. The test was performed according to the manufacturer’s instructions using a 300-l
sample volume. Results were provided in approximately 30 min, with a hands-on time of less than 5 min.
BD Veritor Flu A/B antigen test. The BD Veritor Flu A/B antigen test is a chromatographic
immunoassay and RIDT for qualitative detection of inﬂuenza A and B viral nucleoprotein antigens in
respiratory specimens, with an instrument-based objective digital readout. The test uses a 300-l sample
volume. The results are obtained in less than 15 min. The test result from this standard-of-care assay was
recorded and compared with the results from the molecular assays.
Data analysis. Overall Flu prevalence among the study participants was determined as per the CDC
Flu A/B PCR assay (reference method). Age and symptom distribution among the Flu-positive and
-negative groups were determined and statistically compared using Fisher’s exact two-tailed test. In
addition, we ﬁt a multivariable logistic regression model for examining the likelihood of testing positive
for inﬂuenza in relation to clinical symptoms such as cough, sore throat, myalgia, conjunctivitis, and
fever.
Two-by-two data tables were used to determine the sensitivity and speciﬁcity of all four Flu
diagnostic assays in comparison with the reference method. The true-positive (TP), true-negative (TN),
false-positive (FP), and false-negative (FN) categories were determined based on the reference method.
Estimates along with 95% conﬁdence intervals (CI) presented in Tables 2 and 3 were calculated from the
site http://vassarstats.net/clin1.html.

RESULTS
A total of 201 pediatric subjects with clinical symptoms suggestive of inﬂuenza
infection were enrolled in this prospective study after informed consent was obtained.
The median age for study subjects was 42 months (range, 0 to 200 months). Fever
(96.5%), cough (86.6%), and fatigue (76.1%) were the most common symptoms observed in enrolled children. The presenting clinical symptoms that showed statistical
signiﬁcance (P ⬍ 0.05) between the Flu-positive and -negative groups by the CDC Flu
A/B PCR assay were cough, fatigue, headache, myalgia, sore throat, and conjunctivitis.
The multivariable logistic regression model revealed an increased likelihood of testing
inﬂuenza positive when the patient presented with cough (adjusted odds ratio [aOR],
3.1), sore throat (aOR, 2.5), myalgia (aOR, 2.2), or conjunctivitis (aOR, 1.9). The number
of days from onset of illness to date of enrollment for all 201 subjects and individual
Flu-positive and -negative groups was similar (median [range], 1 [0 to 3] days). Detailed
patient demographic and clinical information is listed in Table 1.
Inﬂuenza virus. The CDC Flu A/B PCR assay detected 73 Flu A and 36 Flu B cases
among the 201 tested samples. The median (range) threshold cycle (CT) values for Flu
A virus and Flu B virus were 23.3 (15.9 to 38.5) and 22.9 (16.9 to 36.5), respectively. Two
samples were positive for both the Flu A and Flu B viruses. Subtyping of the 73 Flu A
virus specimens with H1N1- and H3N2-speciﬁc primers detected 31 pH1N1 and 40
H3N2 strains. Two Flu A virus-positive strains remained untyped. Of the 36 Flu B virus
specimens, 33 belonged to the Yamagata lineage, and the remaining 3 specimens
could not be typed. We did not ﬁnd any Victoria lineage strains among these samples.
Flu A virus. The three molecular platforms, ID Now, LIAT, and Xpert, were positive
for 69, 74, and 76 samples, respectively, with a sensitivity of 100% for the LIAT and the
Xpert assay and 93.2% for the ID Now assay. All ﬁve false-negative samples for the ID
Now assay belonged to the pH1N1 subtype and had a high median CT value of 33.81
(range, 31.8 to 36.0) by the CDC Flu A/B PCR assay, suggesting low viral load. The
antigen-based BD assay demonstrated a lower sensitivity of 79.5%, with overall 59
March 2020 Volume 58 Issue 3 e01611-19
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TABLE 1 Clinical characteristics overall and by Flu virus detection results as determined
by the CDC Flu A/B PCR assay
No. (%) in group:
Overall
(n ⴝ 201)
194 (96.5)
174 (86.6)
153 (76.1)
91 (45.3)
84 (41.8)
78 (38.8)
77 (38.3)
75 (37.3)
72 (35.8)
70 (34.8)
56 (27.9)
53 (26.4)
40 (19.9)

Flu-positive
result (n ⴝ 107)
103 (96.3)
100 (93.5)
89 (83.2)
61 (57.0)
57 (53.3)
55 (51.4)
38 (35.5)
46 (43.0)
47 (43.9)
36 (33.6)
30 (28.0)
24 (22.4)
19 (17.8)

Flu-negative
result (n ⴝ 94)
91 (96.8)
74 (78.7)
64 (68.1)
30 (31.9)
27 (28.7)
23 (24.5)
39 (41.5)
29 (30.9)
25 (26.6)
34 (36.2)
26 (27.7)
29 (30.9)
21 (22.3)

P value
1.0
0.003
0.01
⬍0.001
⬍0.001
⬍0.001
0.47
0.08
0.01
0.77
1.0
0.2
0.48
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Clinical
characteristic
Fever
Cough
Fatigue
Headache
Myalgias
Sore throat
Dyspnea
Abdominal pain
Conjunctivitis
Wheezing
Vomiting
Earache
Diarrhea

positive Flu A virus detections and 15 FN results compared with the CDC Flu A/B PCR
assay. The median CT value for these 15 FN samples was 29.04 (range, 19.12 to 39.86)
by the CDC Flu A/B PCR method. The speciﬁcity for the ID Now assay, LIAT, and BD assay
was greater than 99%; the Xpert assay demonstrated a speciﬁcity of 97.7%, with three
FP results. Table 2 depicts the details of all performance parameters.
Flu B virus. Among the three molecular assays, ID Now showed the highest
sensitivity of 97.2%, followed by LIAT and Xpert, with sensitivities of 94.4% and 91.7%,
respectively. The speciﬁcities of all three molecular assays were greater than 97%. The
LIAT had four FP Flu B virus results, followed by the Xpert (n ⫽ 3) and ID Now (n ⫽ 2)
assays. Of the 36 Flu B specimens detected by the CDC Flu A/B PCR assay, BD detected
only 24 positives, with a sensitivity of 66.7%. The 12 FN samples had a median CT value
of 28.1, ranging from 16.85 to 36.46. The details of all performance parameters are listed
in Table 2.
Invalid results. Sample results were considered invalid if an instrument error was
obtained or there was a failure to generate a result. The number of invalid results was
highest for the LIAT (n ⫽ 11 [5.5%]), followed by Xpert (n ⫽ 6 [3.0%]) and ID Now (n ⫽ 1
[0.5%]). Repeat testing resulted in valid results for all affected samples. The rate of
invalid runs for BD was undetermined since historic data were used for this platform.
Early versus full-callout mode of the ID Now assay. A total of 102 samples were
run on both the early and full-callout modes. The time for a positive call on the early

TABLE 2 Performances of the ID Now, LIAT, Xpert, and BD assays versus that of the CDC
Flu A/B PCR assay
No. with resulta:

% (95% CI) for:

Virus
target
Flu A
Flu B

TP
68
35

FP
1
2

TN
127
163

FN
5
1

Sensitivity
93.2 (84.1–97.5)
97.2 (83.8–99.9)

Speciﬁcity
99.2 (95.1–100.0)
98.8 (95.2–99.8)

LIAT

Flu A
Flu B

73
34

1
4

127
161

0
2

100 (93.8–100)
94.4 (80.0–99.0)

99.2 (95.1–100.0)
97.6 (93.5–99.2)

Xpert

Flu A
Flu B

73
33

3
3

125
162

0
3

100 (93.8–100)
91.7 (76.4–97.8)

97.7 (92.8–99.4)
98.2 (94.4–99.5)

BDb

Flu A
Flu B

58
24

1
1

126
163

15
12

79.5 (68.1–87.7)
66.7 (48.9–80.9)

99.2 (95.0–99.9)
99.4 (96.1–99.9)

Assay
ID Now

aTP,

true positive; FP, false positive; TN, true negative; FN, false negative. The number of dual Flu A/Bpositive results were 2 for the CDC Flu A/B PCR, 4 for the ID Now assay, 0 for the LIAT, 0 for the Xpert
assay, and 0 for the BD assay.
bBD results were available for 200 subjects. Standard-of-care testing for one subject was PCR based.
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TABLE 3 Performance characteristics of the ID Now assay on full- versus early callout
mode
No. with resulta:

% (95% CI) for:

ID Now assay
callout mode
Full

Virus
target
Flu A
Flu B

TP
23
21

TN
78
79

FP
0
2

FN
1
0

Sensitivity
95.8 (76.9–99.8)
100 (80.8–100)

Speciﬁcity
100 (94.2–100)
97.5 (90.5–99.6)

Early

Flu A
Flu B

23
21

78
77

0
4

1
0

95.8 (76.9–99.8)
100 (80.8–100)

100 (94.2–100)
95.1 (87.2–98.4)

aTP,

true positive; FP, false positive; TN, true negative; FN, false negative.
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callout mode was less than 9 min, including the sample setup time. The assay run time
for Flu B-positive results was observed to be faster than for Flu A-positive results
(median [range], 3 [2 to 4] min for Flu B virus versus 4 [3 to 5] min for Flu A virus). The
negative samples underwent a full cycle of approximately 13 min before the negative
result call. The performances of the assay on the two callout modes were found to be
comparable as well. The sensitivities for Flu A/B virus detection on both modes were
found to be 95.8% and 100%, respectively. The speciﬁcity for Flu A virus detection was
100% for both modes, but the speciﬁcity for Flu B virus detection on the early callout
mode was slightly lower than that on the full-callout mode (95.1% versus 97.5%,
respectively). Detailed performance characteristics for both modes are given in Table 3.
DISCUSSION
CLIA-waived rapid molecular assays are widely used as point-of-care assays for Flu
virus detection in the clinical setting due to their high sensitivity and speciﬁcity, ease
of use, and short turnaround time. The ID Now (Abbott) inﬂuenza A & B 2 assay,
formerly the Alere i inﬂuenza A/B 2 assay, is the latest improved version of the Alere i
inﬂuenza A/B assay. The ID Now inﬂuenza A & B 2 assay has incorporated signiﬁcant
changes to both the ampliﬁcation reaction and the analytical software compared to the
original Alere i inﬂuenza A/B assay. In this prospective study, we compared the
performance characteristics of three CLIA-waived molecular platforms, LIAT, ID Now,
and Xpert, for Flu virus detection in a pediatric population compared with the CDC Flu
A/B PCR. BD results from standard-of-care testing were also used to compare the
performances of the molecular detection platforms with this RIDT platform. The sensitivities for Flu A virus/Flu B virus (respectively) detection for the assays were as follows:
93.2%/97.2% for the ID Now assay, 100%/94.4% for the LIAT; 100%/91.7% for the Xpert
assay, and 79.5%/66.7% for the BD assay. The speciﬁcities for the detection of both Flu
A and B viruses were found to be greater than 97% for all assays. The invalid rate was
lowest for the ID Now assay (0.5%) compared with the LIAT (5.5%) and the Xpert assay
(3%). The time to result on the new ID Now platform for a positive sample was found
to be less than 9 min in the early test mode, with performance similar to that of the
full-callout mode.
The BD assay had lower sensitivity for both Flu A virus (79.5%) and Flu B virus
(66.7%) than did all three molecular assays. The speciﬁcity of BD was comparable to
that of the molecular assays. According to a recent meta-analysis (7) that included six
studies evaluating the BD assay for Flu virus detection, sensitivity ranged from 64% to
94% for both Flu A and B virus detection. The difference in sensitivity is well acknowledged between an RIDT and a molecular assay. The same meta-analysis study (7)
included seven studies for the Alere i assay and ﬁve studies for the LIAT. Although the
pooled speciﬁcities for both assays for Flu A and B virus detection were found to be
comparable (approximately 99%), a 12.4% difference in pooled Flu A virus detection
sensitivity (Alere i, 84.4%; versus LIAT, 97.1%) and an 11.8% difference in Flu B virus
detection sensitivity (Alere i, 86.6%; versus LIAT, 98.7%) were noted. The meta-analysis
included studies from both the pediatric and adult populations. The new version of the
ID Now assay appears to have signiﬁcant improvement in Flu A and B virus detection,
with Flu A virus sensitivity of 93.2% and Flu B virus sensitivity of 97.2%. The sensitivity
March 2020 Volume 58 Issue 3 e01611-19
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for Flu B virus detection for the ID Now assay was found to be greater than for the LIAT
(97.2% versus 94.4%, respectively).
Several studies have evaluated the performances of the Alere i inﬂuenza A & B, LIAT,
and Xpert assays. The reported sensitivity for the Alere i assay for Flu B virus detection
has ranged from 45.2% to 100% (9–15). The newer version evaluated in this study (ID
Now) seemed to have improved sensitivity and speciﬁcity for both Flu A and Flu B virus
detection. The performance parameters were found to be slightly higher than those of
the other two molecular assays for Flu B virus detection. Among the 201 samples we
tested in this study, only two (0.9%) samples were Flu B virus false-positive samples.
These two FP samples for Flu B virus were also positive for Flu A virus by the ID Now
assay. A higher number of FP results for Flu B virus was observed with the LIAT (n ⫽ 3
[1.5%]) and Xpert (n ⫽ 4 [2.0%]). The FP Flu B virus detection rate was comparable to
the Flu B virus false results observed for the LIAT and the Xpert assay in our study.
Early Flu diagnosis is critical for patient management and reduction of morbidity
and mortality during seasonal epidemics and pandemics (16). The assay processing
time for the ID Now assay (approximately 13 min on the full-callout mode and less than
5 min on the early callout mode for a positive result) was faster than for the LIAT (20
min) and Xpert assay (30 min). Specimen processing for the ID Now assay was
straightforward and took approximately 5 min in a few simple steps (the basic components of the test are the same as those of the previous versions; however, in the new
version, the warm-up time required for the sample elution buffer is reduced by half,
from 6 min to 3 min for both universal transport medium [UTM] and swab samples). The
LIAT and the Xpert assay only required adding the sample to the cartridge. Other
considerations for the point-of-care assay include an additional testing menu to limit
multiple testing platforms, throughput, device footprint, sample volume, capability to
interface with the laboratory information systems (LIS), storage space, and temperature
conditions for the test devices. The three assays were comparable for most of these
variables. GeneXpert systems that are suitable for most point-of-care settings are
available in one-, two-, or four-module conﬁgurations. The Cepheid GeneXpert Xpress
II system was used for this study. This instrument has the capacity to process two
samples simultaneously and has random-access capability. The LIAT and the ID Now
assay can handle only one sample at a time, but multiple instruments can be used to
supplement additional testing. The linear square foot requirement was relatively
greater for the Xpert II system (approximately 0.5 square feet) than with the ID Now
assay (approximately 0.4 square feet) and the LIAT (approximately 0.3 square feet). In
addition to the equipment, an additional benchtop area for a laptop may also be a
consideration for Xpert. The LIAT required the kits to be stored at refrigeration
temperatures, as opposed to the ID Now and Xpert assays, where the test kits could be
stored at room temperature. Moreover, with the ⬍5-min turnaround time with the ID
Now early callout mode, results could be provided to the physician quickly, aiding in
timely initiation of antiviral therapy and reduced health care costs, making it more
suitable for the outpatient setting as a point-of-care assay.
The invalid rate is another important consideration when selecting an assay for
clinical use. The invalid rate for the ID Now assay was signiﬁcantly lower than that for
the LIAT (0.5% versus 5.5%, respectively; P ⫽ 0.006) or the Xpert assay (0.5% versus 3%,
respectively; P ⫽ 0.12), but the difference did not reach statistical signiﬁcance. The
retests performed on all assays yielded valid results. The invalid rate not only could add
to laboratory costs but also cause a delay in reporting results. Earlier studies with the
Alere i version reported invalid rates ranging from 0.5% to 4.2% (11–13, 17); there may
be an improvement in the invalid rate as well with the current ID Now assay.
Strengths of our study include the prospective study design in which the subjects
were enrolled systematically and a single NP swab specimen obtained to evaluate the
performances of all 3 molecular assays. Study limitations include the fact that all three
CLIA-waived molecular assays were evaluated by laboratory personnel and not in the
point-of-care setting. Performance characteristics may differ when assays are performed
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by laboratory personnel rather than by clinical personnel in the point-of-care setting
(18).
Overall, the performances of all three molecular assays were found to be comparable. ID Now is a CLIA-waived, simple-to-use molecular assay in which positive results
can be obtained within 5 min. This advantage makes the assay suitable for point-of-care
testing in an outpatient setting.
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